Robert Williamson III

Robert F. Williamson, III is the CEO of privately held PharmAkea, a fibrosis drug development company financed through a build-to-buy partnership with Celgene (NASDAQ: CELG) and is Director of privately held Naia Limited, a global drug development company. He has been active in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers. Previously, as a Director, he helped finance, grow, take public and sell Pharmasset, Inc. (NASDAQ: VRUS), which was bought by Gilead (NASDAQ:GILD) for $11B. He was also appointed to the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen, and has been on numerous private company boards. Earlier, Mr. Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology - which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc. - which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT). Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc., and his clients included top pharmaceutical, medical device and health care companies with additional clients in high technology and energy. Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C. where he supported monetary policy under Alan Greenspan. He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford Graduate School of Business.